GABA a receptor target of tetramethylenedisulfotetramine

Abstract

Use of the highly toxic and easily prepared rodenticide tetramethylenedisulfotetramine (TETS) was banned after thousands of accidental or intentional human poisonings, but it is of continued concern as a chemical threat agent. TETS is a noncompetitive blocker of the GABA type A receptor (GABA A R), but its molecular interaction has not been directly established for lack of a suitable radioligand to localize the binding site. We synthesized [ 14 C] TETS (14 mCi/mmol, radiochemical purity >99%) by reacting sulfamide with H 14 CHO and s-trioxane then completion of the sequential cyclization with excess HCHO. The outstanding radiocarbon sensitivity of accelerator mass spectrometry (AMS) allowed the use of [ 14 C]TETS in neuroreceptor binding studies with rat brain membranes in comparison with the standard GABA A R radioligand 4′-ethynyl-4- n-[ 3 H]propylbicycloorthobenzoate ([ 3 H]EBOB) (46 Ci/mmol), illustrating the use of AMS for characterizing the binding sites of high-affinity 14 C radioligands. Fourteen noncompetitive antagonists of widely diverse chemotypes assayed at 1 or 10 μM inhibited [ 14 C]TETS and [ 3 H]EBOB binding to a similar extent (r 2 = 0.71). Molecular dynamics simulations of these 14 toxicants in the pore region of the α1β2γ2 GABA A R predict unique and significant polar interactions for TETS with α 1 T1′ and γ 2 S2′, which are not observed for EBOB or the GABAergic insecticides. Several GABA A R modulators similarly inhibited [ 14 C]TETS and [ 3 H]EBOB binding, including midazolam, flurazepam, avermectin Ba1, baclofen, isoguvacine, and propofol, at 1 or 10 μM, providing an in vitro system for recognizing candidate antidotes.